Introduction to purchasing channels and therapeutic effects of Ripotinib

Introduction: Repotrectinib, also known as Ripotinib, is a new generation ROS1 inhibitor targeting ROS1 fusion-positive non-small cell lung cancer (NSCLC) and advanced gastrointestinal stromal tumors (GIST). It works by inhibiting ROS1, TRKA, TRKB and TRKC, has multi-target broad-spectrum anti-cancer properties, and has shown good efficacy and safety in clinical studies. This article mainly talks about the purchasing channels, time to market, adverse reactions and management, treatment effects, etc. of Ripotinib.

Purchasing channels for generic versions of Ripotinib

1. Hospital pharmacies: Patients can ask whether generic versions of Ripotinib are for sale in hospitals with pharmacies.

2. Online pharmacies: Some formal online drug sales platforms may provide purchase services for generic drugs of Ripotinib.

3. Overseas medical service institutions: If it is difficult to obtain it domestically, patients can obtain it through the help of domestic professional overseas medical service institutions. The drugs can be mailed to their homes, ensuring that they are genuine and more cost-effective.

Time to market

Ripotinib was approved by the FDA on November 15, 2023 in the United States.

In China, Ripotinib capsules (trade name: Augtyro) were approved by the National Medical Products Administration on May 11, 2024.

Currently, we know that there are already generic versions of Ripotinib on the market internationally.

Adverse reactions and management

Some side effects may occur when using repotinib, such as hair loss, fatigue, nausea, abdominal pain, constipation, muscle pain, diarrhea, loss of appetite and vomiting. Some patients may experience increased blood pressure or cardiac dysfunction after taking Ripotinib. Therefore, you need to pay attention to these potential side effects when using Ripotinib and use it under the guidance of a doctor.

Treatment effect

1. Efficacy in TKI-naïve patients: In the TRIDENT-1 study, 56 (79%) of 71 ROS1-positive NSCLC patients who had not received ROS1-TKI treatment before experienced response, with the median duration of response (mDOR) being 34.1 months and the median progression-free survival (mPFS) being 35.7 months.

2. Efficacy of TKI-experienced patients: Among 56 ROS1-positive NSCLC patients who had received one ROS1-TKI treatment in the past but had never received chemotherapy, 21 patients (38%) experienced remission, with a median DOR of 14.8 months and a median PFS of 9.0 months.

3. Intracranial efficacy: Ripotinib has also shown a relatively strong ability to alleviate intracranial lesions in patients with brain metastases. Among patients with measurable brain metastases at baseline, intracranial responses were observed in 7 of 8 TKI-naïve patients and in 5 of 12 TKI-experienced patients.

4. Efficacy of drug-resistant mutations: Ripotinib can overcome all known ALK, ROS1 and NTRK drug-resistant problems that appear in clinical practice, including ROS1 G2032R mutations.

As a new type of targeted therapy, it provides a new treatment option for patients with ROS1-positive NSCLC. Patients should follow their doctor's prescription instructions when using repotinib and maintain communication with their doctor during treatment so that any potential problems can be dealt with in a timely manner.